Brief: Poxel Announces Submission Of Imeglimin Japanese New Drug Application

Poxel SA

30/07/2020 07:36

July 30 (Reuters) - POXEL SA  POXEL.PA :
    * ANNOUNCES SUBMISSION OF IMEGLIMIN JAPANESE NEW DRUG
APPLICATION
FOR THE TREATMENT OF TYPE 2 DIABETES BY SUMITOMO DAINIPPON
PHARMA
    * J-NDA SUBMISSION TRIGGERS 500 MILLION (EUR 4.1 MILLION,
$4.7
MILLION)* DEVELOPMENT MILESTONE PAYMENT TO POXEL
    * POTENTIAL FOR 1.75 BILLION (APPROXIMATELY EUR 14.2
MILLION,
$16.6 MILLION)* MILESTONE PAYMENT UPON PRODUCT APPROVAL
    * PENDING AVERAGE J-NDA REVIEW PERIOD, IMEGLIMIN'S TARGET
PRODUCT
LAUNCH ANTICIPATED IN FISCAL YEAR 2021
    * JAPANESE NEW DRUG APPLICATION (J-NDA) FOR IMEGLIMIN
SUPPORTED BY
POSITIVE RESULTS FROM PHASE 3 TIMES PROGRAM IN OVER 1,100
PATIENTS IN JAPAN

Source text for Eikon:  ID:nBw7YFYda 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587785110;))